Replies to post #172455 on Biotech Values

[mcbio]

However, isn't it an achievement to be granted passage to Phase 3?

I would respectfully submit: no, not really. Lots of drugs make it to Phase 3 that really haven't shown much activity to date and go on to fail in Phase 3. Small-cap companies that have limited assets have an incentive to continue to carry on trials of their key drug, regardless of clinical robustness to date and chances of success going forward, lest they not look viable (that has been called Zebra's Law on here).

Regarding the science, I've made numerous post challenging Anti-PS. I've theorized that Bavituximab loses it's ability to stay bound long enough for therapeutic benefit. I've theorized that phosphatidylserine roll in cell signaling, coagulation and normal apoptotic cycle may be substantial, but blocking it may be inconsequential. I've posted how and why for many of my theories, but for what ever reason I'm still intrigued by the possibilities.

Believe me, I hope it works for patients and PPHM investors. I'm just very skeptical based on the limited evidence to date.